|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 24, 2012 ) New York, NY -- VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, identifies a few stocks that were bucking the market trend during the early-week sell-off.
This is an abbreviated report. For full report visit: http://vfcsstockhouse.com/blog/article/-encouraging-trial-news-helps-sunshine-heart-buck-the-market-trend
The DOW dropped by over a hundred points on Monday as the broad markets failed to ward off jitters of a weakening global economy and additional economic chaos in Europe sparked by the threat of Spain and Greece each needing additional bailouts. These fears were already lingering in the minds of investors for weeks, but a weak quarterly report by McDonald's (MCD) on Monday brought these concerns to the forefront and sparked a widespread sell-off.
There were some winners out there, though. Implant Sciences (IMSC) managed a five percent jump amid the madness as the company received some key media coverage highlighting the potential of the company's products to lead the next wave of providing airport security while Synergy Pharmaceuticals (SGYP) also spent the majority of the day trading higher after last week's merger announcement.
Additionally, as noted earlier, a couple of high profile FDA approval dates are pending for this week, with both Amarin Corp (AMRN) and Horizon Pharma (HZNP) slated to receive word from the FDA on the 26th. Both stocks held up well during the downturn as Horizon jumped by seven percent while Amarin, after nice high-volumed early morning boost, closed the day at just under even.
One of the biggest winners of the day on Monday, however, was Sunshine Heart (SSH), which again made the Nasdaq's list of early day gainers.
Sunshine has retreated back to the ten dollar mark over the past few trading sessions after having ran from roughly three dollars to over seventeen in a short period of time, but SSH was on the move again to open the new trading week after announcing a positive two year review of the first patient to have been implanted with the company's C-Pulse heart assist system in conjunction with its North America feasibility trial, which is testing the device in the treatment of Class III and Ambulatory Class IV heart failure. Enrollment for the trial was completed in June of last year, so data should roll in swiftly enough to keep the company on its expected timeline of initiated a key definitive trial in the US later this year, right around the same time that the company could register its first commercial sales in Europe, pending the outcome of the CE Mark approval for which Sunshine has sought.
For this week's list of hot stocks to watch visit: http://vfcsstockhouse.com/blog/article/-weekly-stock-watch-week-of-july-23-amrn-hznp-aapl-amzn-fb-cmcsa-yhoo-yum-mcd-ko-pep-goog-msft-ge-cat-cmi-hgsi-gsk-ssh-actc-imsc-mric-bsx-si-tlle-t-lptn-pfe
Contact VFC's Stock House: vfc@vfcsstockhouse.com
Originally published at: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
